Product Comparison


 
Glaxo Specialty 49702025315
Glaxo Specialty 49702024015
McKesson # 1184407 1184408
Description CABENUVA Cabotegravir / Rilpivirine 400 mg - 600 mg Injection Single-Dose Kit 2 mL - 2 mL CABENUVA Cabotegravir / Rilpivirine 600 mg - 900 mg Injection Single-Dose Kit 3 mL - 3 mL
Manufacturer # 4970202531549702024015
Brand CABENUVACABENUVA
Manufacturer Glaxo SpecialtyGlaxo Specialty
Invoice CABENUVA KIT, SDV 400MG/600MGCABENUVA KIT, SDV 600MG/900MG
    Log In to Order   Log In to Order

Comparison

NDC Number 4970202531549702024015
Strength 400 mg - 600 mg600 mg - 900 mg
Volume 2 mL - 2 mL3 mL - 3 mL
Application HIV Integrase Inhibitor and HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorHIV Integrase Inhibitor and HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor
Container Type Single-Dose KitSingle-Dose Kit
Country of Origin UnknownUnknown
Dosage Form InjectionInjection
Generic Drug Name Cabotegravir / RilpivirineCabotegravir / Rilpivirine
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 days
Storage Requirements Requires RefrigerationRequires Refrigeration
Type IntramuscularIntramuscular
UNSPSC Code 5134380051343800
Features and Benefits
  • CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
  • Requires Refrigeration
  • Intramuscular (IM) gluteal
  • CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine
  • Requires Refrigeration
  • Intramuscular (IM) gluteal